Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : $10 and Under : New 52 Week Highs -- Ignore unavailable to you. Want to Upgrade?

To: ~digs who wrote (244)	11/17/2006 4:57:15 PM
From: ~digs	Respond to of 557

DRAX 5.0 Draxis Health, Inc., through its subsidiary, DRAXIS Specialty Pharmaceuticals, Inc., provides pharmaceutical products in the areas of sterile, including sterile lyophilized pharmaceuticals; nonsterile specialty pharmaceuticals; and radiopharmaceuticals. Its sterile products include liquid and freeze-dried injectables, and sterile ointments. The Company’s nonsterile products are produced as solid oral, liquid, and semi-solid dosage forms. Its radiopharmaceuticals are used for therapeutic and diagnostic molecular imaging applications. The company’s radiopharmaceutical products include BrachySeed, an Iodine-003125 brachytherapy implant, which is used for the treatment of various localized cancers; and MDP-25, a kit for the preparation of Technetium Tc99m Medronate Injection, which is used to demonstrate areas of altered osteogenesis or bone growth. In addition, it provides FIBRIMAGE, a proprietary targeted molecular imaging product to aid in the diagnosis of deep vein thrombosis, is in phase III clinical trial; and SOMATOSCAN, a preclinical stage product, which is used for imaging of neuroendocrine tumors, lymphoma, carcinoid, and small-cell lung cancer. The company has collaboration agreements with Pfizer for the development of Anipryl, which is a selegiline product for use in veterinary prescriptive applications; and GlaxoSmithKline Consumer Healthcare for the development of SpectroPhar line of dermatology products. Thursday November 2, 6:30 am ET Draxis Health Third Quarter on Track for Record Year biz.yahoo.com

To: ~digs who wrote (244)	11/17/2006 5:03:54 PM
From: ~digs	Respond to of 557

OME 6.8 Omega Protein Corporation engages in the processing, marketing, and distribution of fish meal and fish oil products in the United States. It produces and sells a range of protein and oil products derived from menhaden, a species of wild herring-like fish found along the Gulf of Mexico and Atlantic coasts. The company processes various grades of fish meal that include Special Select, SeaLac, and FAQ Meal; crude unrefined fish oil, refined fish oil, and food grade oil; and fish solubles, such as Neptune Fish Concentrate, OmegaGrow, and OmegaGrow Plus. Omega’s fish meal products are primarily used as a protein ingredient in animal feed for swine, cattle, aquaculture, and household pets; fish oil is utilized for animal and aquaculture feeds, industrial applications, additives to human food products, and as dietary supplements. It offers fish solubles primarily to livestock feed manufacturers, aquaculture feed manufacturers, and for use as an organic fertilizer. Monday November 6, 6:31 pm ET Omega Protein Corporation today reported net income of $1.8 million (7 cents a share) for the third quarter of 2006, compared with a net loss of $6.1 million (25 cents a share) for the third quarter of the previous year. Revenues for the third quarter ended September 30, 2006 were $52.1 million compared with revenues of $31.4 million for the comparable quarter in 2005. biz.yahoo.com